Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

727 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A20 controls intestinal homeostasis through cell-specific activities.
Vereecke L, Vieira-Silva S, Billiet T, van Es JH, Mc Guire C, Slowicka K, Sze M, van den Born M, De Hertogh G, Clevers H, Raes J, Rutgeerts P, Vermeire S, Beyaert R, van Loo G. Vereecke L, et al. Among authors: rutgeerts p. Nat Commun. 2014 Sep 30;5:5103. doi: 10.1038/ncomms6103. Nat Commun. 2014. PMID: 25267258 Free article.
C-reactive protein as a marker for inflammatory bowel disease.
Vermeire S, Van Assche G, Rutgeerts P. Vermeire S, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2004 Sep;10(5):661-5. doi: 10.1097/00054725-200409000-00026. Inflamm Bowel Dis. 2004. PMID: 15472532 Review.
Novel biological strategies in inflammatory bowel diseases.
Vermeire S, Rutgeerts P. Vermeire S, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2004 Feb;10 Suppl 1:S44-51. doi: 10.1097/00054725-200402001-00010. Inflamm Bowel Dis. 2004. PMID: 15168831 Review. No abstract available.
Biological therapies for inflammatory bowel diseases.
Rutgeerts P, Vermeire S, Van Assche G. Rutgeerts P, et al. Gastroenterology. 2009 Apr;136(4):1182-97. doi: 10.1053/j.gastro.2009.02.001. Epub 2009 Feb 26. Gastroenterology. 2009. PMID: 19249397 Review.
Targeting TNF-α for the treatment of inflammatory bowel disease.
Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Billiet T, et al. Among authors: rutgeerts p. Expert Opin Biol Ther. 2014 Jan;14(1):75-101. doi: 10.1517/14712598.2014.858695. Epub 2013 Nov 11. Expert Opin Biol Ther. 2014. PMID: 24206084 Review.
Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease.
de Bruyn M, Machiels K, Vandooren J, Lemmens B, Van Lommel L, Breynaert C, Van der Goten J, Staelens D, Billiet T, De Hertogh G, Ferrante M, Van Assche G, Vermeire S, Opdenakker G, Schuit F, Rutgeerts P, Arijs I. de Bruyn M, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2014 Feb;20(2):339-52. doi: 10.1097/01.MIB.0000438430.15553.90. Inflamm Bowel Dis. 2014. PMID: 24378596 Clinical Trial.
727 results